potterclarkson-1
ANASTASIA TVERETINOVA / SHUTTERSTOCK.COM
27 October 2015PharmaSteve Smith

Pharma patents: Growing pains for second medical use inventions

It is 30 years since the European Patent Office (EPO) endorsed the practice of claiming new medical uses of known agents in the ‘Swiss-type’ claim format, namely “use of substance X in the preparation of a medicament/pharmaceutical composition for treating indication Y”. During that time, however, surprisingly little guidance on the scope and infringement of such claims has been forthcoming from the case law of the national courts in Europe—until now.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
17 September 2026   Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.
Pharma
16 September 2026   A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
Pharma
10 September 2026   Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.